Schrodinger, Inc. (NASDAQ:SDGR) Receives Average Rating of "Hold" from Analysts
Schrodinger, Inc. (NASDAQ:SDGR) has received an average rating of 'Hold' from seven research firms. The stock has one sell, three hold, and three buy recommendations. The average 12-month price target is $26.00. Recent analyst actions include downgrades and price target reductions. Insider Margaret Dugan sold shares, and institutional investors have adjusted their positions. Schrodinger reported better-than-expected Q3 earnings with a 53.9% revenue increase. The company focuses on software and drug discovery.
Shares of Schrodinger, Inc. (NASDAQ:SDGR - Get Free Report) have been assigned an average recommendation of "Hold" from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $26.00.
- 3 Momentum Stocks That Could Soar Post-Market Volatility
A number of equities analysts recently issued reports on the stock. Morgan Stanley decreased their price target on shares of Schrodinger from $28.00 to $19.00 and set an "equal weight" rating for the company in a research note on Monday, August 18th. Wall Street Zen raised Schrodinger from a "sell" rating to a "hold" rating in a research report on Saturday, October 25th. Weiss Ratings restated a "sell (e+)" rating on shares of Schrodinger in a research note on Tuesday, October 14th. KeyCorp reduced their price target on Schrodinger from $30.00 to $28.00 and set an "overweight" rating on the stock in a research note on Wednesday, October 8th. Finally, Citigroup downgraded Schrodinger from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $35.00 to $20.00 in a report on Friday, August 15th.
Get Our Latest Stock Report on SDGR
Insider Transactions at Schrodinger
- AI Pharma: 2 Paths to AI-Powered Drug Investment
In other news, insider Margaret Dugan sold 1,395 shares of Schrodinger stock in a transaction dated Thursday, October 16th. The stock was sold at an average price of $21.07, for a total value of $29,392.65. Following the completion of the transaction, the insider owned 24,574 shares of the company's stock, valued at $517,774.18. The trade was a 5.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 21.00% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the company. CANADA LIFE ASSURANCE Co increased its position in Schrodinger by 4.7% in the third quarter. CANADA LIFE ASSURANCE Co now owns 66,520 shares of the company's stock worth $1,332,000 after buying an additional 2,995 shares in the last quarter. PharVision Advisers LLC bought a new position in shares of Schrodinger during the 3rd quarter valued at approximately $286,000. XTX Topco Ltd increased its holdings in Schrodinger by 82.2% in the 3rd quarter. XTX Topco Ltd now owns 53,596 shares of the company's stock worth $1,075,000 after acquiring an additional 24,172 shares in the last quarter. Verity Asset Management Inc. raised its stake in Schrodinger by 43.5% during the 3rd quarter. Verity Asset Management Inc. now owns 64,924 shares of the company's stock worth $1,302,000 after acquiring an additional 19,673 shares during the period. Finally, Quarry LP raised its stake in Schrodinger by 73.6% during the 3rd quarter. Quarry LP now owns 2,401 shares of the company's stock worth $48,000 after acquiring an additional 1,018 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.
Schrodinger Stock Performance
- Simulations Plus Stock Drops 15% Despite EPS Beat
Shares of Schrodinger stock opened at $16.47 on Friday. Schrodinger has a 52-week low of $15.99 and a 52-week high of $28.47. The company has a fifty day moving average of $19.63 and a 200-day moving average of $20.62. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -6.83 and a beta of 1.77.
Schrodinger (NASDAQ:SDGR - Get Free Report) last issued its earnings results on Wednesday, November 5th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.27. The company had revenue of $54.32 million during the quarter, compared to analysts' expectations of $50.51 million. Schrodinger had a negative return on equity of 48.24% and a negative net margin of 68.49%.Schrodinger's quarterly revenue was up 53.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.87) EPS. Schrodinger has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Schrodinger will post -2.37 earnings per share for the current fiscal year.
About Schrodinger
(Get Free Report)Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.
See Also
- Five stocks we like better than Schrodinger
- Most active stocks: Dollar volume vs share volume
- MP Materials Stock Soared After Earnings—Here’s the Real Reason
- Asset Allocation Strategies in Volatile Markets
- Why Palantir Slide May Be a Setup for a Long-Term Opportunity
- The 3 Best Blue-Chip Stocks to Buy Now
- Attention Income Investors: This REIT Is on Sale
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Schrodinger Right Now?
Before you consider Schrodinger, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Schrodinger wasn't on the list.
While Schrodinger currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
